ID: ALA4851480

Max Phase: Preclinical

Molecular Formula: C23H21F3N4O3

Molecular Weight: 458.44

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)NC(=O)c1cc(-c2ccc(NC(=O)[C@H](O)c3cc(F)cc(F)c3)cc2F)cnc1N

Standard InChI:  InChI=1S/C23H21F3N4O3/c1-11(2)29-22(32)18-7-13(10-28-21(18)27)17-4-3-16(9-19(17)26)30-23(33)20(31)12-5-14(24)8-15(25)6-12/h3-11,20,31H,1-2H3,(H2,27,28)(H,29,32)(H,30,33)/t20-/m1/s1

Standard InChI Key:  LBLBTNIBKKNQAH-HXUWFJFHSA-N

Associated Targets(Human)

Eukaryotic translation initiation factor 2-alpha kinase 3 635 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Eukaryotic translation initiation factor 2 subunit 1 143 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 458.44Molecular Weight (Monoisotopic): 458.1566AlogP: 3.56#Rotatable Bonds: 6
Polar Surface Area: 117.34Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.92CX Basic pKa: 4.85CX LogP: 3.45CX LogD: 3.45
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.45Np Likeness Score: -1.13

References

1. Calvo V, Surguladze D, Li AH, Surman MD, Malibhatla S, Bandaru M, Jonnalagadda SK, Adarasandi R, Velmala M, Singireddi DRP, Velpuri M, Nareddy BR, Sastry V, Mandati C, Guguloth R, Siddiqui S, Patil BS, Chad E, Wolfley J, Gasparek J, Feldman K, Betzenhauser M, Wiens B, Koszelak-Rosenblum M, Zhu G, Du H, Rigby AC, Mulvihill MJ..  (2021)  Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.,  43  [PMID:33895276] [10.1016/j.bmcl.2021.128058]

Source